ASTRAZENECA, AVANIR TO INVESTIGATE TREATMENT

AstraZeneca PLC and US group Avanir Pharmaceuticals have agreed to jointly investigate compounds that could yield treatments for the reversal of heart disease. Reverse Cholesterol Transport (RCT) is a natural process that involves the flow of cholesterol from all tissues, including the walls of blood vessels, to the liver, where it can be sent for excretion. RCT enhancing compounds aim to enhance that flow and may potentially be able to reverse existing cardiovascular disease.

Forbes (http://www.forbes.com/business/feeds/afx/2005/07/11/afx2131234.html)